



- (51) **International Patent Classification:**
C07K 16/28 (2006.01) *A61K 39/395* (2006.01)
- (21) **International Application Number:**
PCT/US2023/060207
- (22) **International Filing Date:**
06 January 2023 (06.01.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/266,549 07 January 2022 (07.01.2022) US
- (71) **Applicant:** **VIRIDIAN THERAPEUTICS, INC.**
[US/US]; 203 Crescent Street, Building 17, Suite 102B,
Waltham, Massachusetts 02453 (US).
- (72) **Inventors:** **BEDIAN, Vahe**; 203 Crescent Street, Building 17, Suite 102B, Waltham, Massachusetts 02453 (US).
ZHAO, Yang; 203 Crescent Street, Building 17, Suite 102B, Waltham, Massachusetts 02453 (US).
- (74) **Agent:** **MCEWAN, Przemyslaw, P.** et al.; Goodwin Procter LLP, 100 Northern Avenue, Boston, Massachusetts 02210 (US).

- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

- (54) **Title:** COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE

**VRDN-2700 and Teprotumumab
NHP Serum Concentration**




FIG. 1

- (57) **Abstract:** Antibodies and compositions against IGF-1R and uses thereof are provided herein.

Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*